CD5: T-cell surface glycoprotein CD5
Lymphoid-specific receptor expressed by all T-cells and in a subset of B-cells known as B1a cells.
- Drugs that act on it: 2
- Approved: 0
- In phases 1 to 3: 2
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on CD5, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Antibody-drug conjugate 2
| Telimomab aritox | Phase 2 | Tasly Tianjin Biopharmaceutical Co., Ltd. | Antibody-drug conjugate | Binding agentT-cell surface glycoprotein CD5 binding agent | 0 |
| Zolimomab aritox | Phase 2 | — | Antibody-drug conjugate | Binding agentT-cell surface glycoprotein CD5 binding agent | 0 |
- Allergic rhinitis0.43
- Atopic eczema0.35
- Allergic disease0.34
- Respiratory system disorder0.34
- Deep vein thrombosis0.34
- Abnormal thrombosis0.34
- Neurodegenerative disease0.27
- Hypertrophic cardiomyopathy0.20
- Hypothyroidism0.20
- Ovarian neoplasm0.14
- Diffuse large B-cell lymphoma0.12
- B-cell chronic lymphocytic leukemia0.12
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3712888, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P06127, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets